Amphotericin B
Jacobo Abadi MD1
1 Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY
Editors: Henry M. Adam, MD.
There are many circumstances in which pediatricians today may be involved in the care of patients at risk for systemic fungal infection. Among those at risk are children receiving chemotherapy for neoplastic disease, children infected with human immunodeficiency virus (HIV), and children undergoing immunosuppressive therapy for chronic illnesses or after transplantation. Available since 1960, amphotericin B (Am B) remains the treatment of choice for most serious fungal infections.
A fermentation product of the soil actinomycete Streptomyces nodosus, Am B binds selectively to ergosterol in the cell membrane of susceptible fungi, inducing changes in permeability that can produce lethal cell injury. Pharmacokinetic studies have sown that Am B is absorbed poorly when taken orally, necessitating intravenous administration.